Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit

Core Insights - Apogee Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel biologics for inflammatory and immunology (I&I) markets, targeting conditions such as atopic dermatitis (AD), asthma, and chronic obstructive pulmonary disease (COPD) [2] Company Overview - Apogee Therapeutics aims to provide differentiated efficacy and dosing in the I&I markets, with a particular focus on AD, which is noted as the largest and least penetrated market in this sector [2] - The company is advancing its antibody programs to address limitations of existing therapies by targeting established mechanisms of action and utilizing advanced antibody engineering to enhance properties like half-life [2] - APG777 is the most advanced program of the company, initially developed for the treatment of AD [2] - Apogee has four validated targets in its portfolio and is pursuing best-in-class efficacy through both monotherapies and combinations of its novel antibodies [2] - The company believes its broad pipeline and expertise can deliver significant value and benefits to patients who are underserved by current standard care [2]